These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 31637475

  • 1. Pembrolizumab for anaplastic thyroid cancer: a case study.
    Aghajani MJ, Cooper A, McGuire H, Jeffries T, Saab J, Ismail K, de Souza P, Bray V, Fazekas de St Groth B, Niles N, Roberts TL.
    Cancer Immunol Immunother; 2019 Dec; 68(12):1921-1934. PubMed ID: 31637475
    [Abstract] [Full Text] [Related]

  • 2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 3. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer.
    Yin M, Di G, Bian M.
    Int Immunopharmacol; 2018 Nov; 64():333-339. PubMed ID: 30243069
    [Abstract] [Full Text] [Related]

  • 4. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
    Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC.
    Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
    [Abstract] [Full Text] [Related]

  • 5. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S.
    Br J Cancer; 2018 Nov 11; 119(10):1223-1232. PubMed ID: 30327563
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
    Goh D, Lim KH, Sudirman SRB, Ang MK, Chua MLK, Lim CM.
    Chin Clin Oncol; 2023 Oct 11; 12(5):57. PubMed ID: 37964542
    [Abstract] [Full Text] [Related]

  • 11. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S.
    Oncotarget; 2016 Mar 29; 7(13):17194-211. PubMed ID: 26943572
    [Abstract] [Full Text] [Related]

  • 12. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, Stefanova D, Christos PJ, Scognamiglio T, Tassler AB, Zarnegar R, Fahey TJ, Jin MM, Min IM.
    Clin Cancer Res; 2020 Nov 15; 26(22):6003-6016. PubMed ID: 32887724
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
    Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, Castagna MG, Toti P.
    Endocrine; 2019 Apr 15; 64(1):122-129. PubMed ID: 30762153
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
    Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, Jiang Y.
    J Clin Invest; 2020 May 01; 130(5):2560-2569. PubMed ID: 32027620
    [Abstract] [Full Text] [Related]

  • 19. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, Horst D, Penzkofer T, Spranger J, Keilholz U, Mai K.
    BMC Endocr Disord; 2024 Feb 22; 24(1):25. PubMed ID: 38383419
    [Abstract] [Full Text] [Related]

  • 20. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
    Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B.
    BMC Cancer; 2019 Mar 04; 19(1):196. PubMed ID: 30832606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.